Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study

Psychopharmacology

Volumn 192, Issue 4, 2007, Pages 479-487

  Eser, Daniela ^a   Schüle, Cornelius ^a   Baghai, Thomas ^a   Floesser, Anette ^b   Krebs Brown, Axel ^b   Enunwa, Michaela ^c   De La Motte, Stephan ^c   Engel, Rolf ^a   Kucher, Klaus ^b   Rupprecht, Rainer ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Harrison Clinical Research   (Germany)

Author keywords

Anxiety; CCK 4; Challenge paradigm; Panic disorder; Proof of concept

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; TETRAGASTRIN;

ADULT; ARTICLE; CARDIOVASCULAR RESPONSE; CONCEPT ANALYSIS; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DRUG SCREENING; HEART RATE; HORMONE DETERMINATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR CLINICAL STUDY; NEUROENDOCRINE SYSTEM; PANIC; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRANQUILIZING ACTIVITY;

ADRENOCORTICOTROPIC HORMONE; ADULT; ANALYSIS OF VARIANCE; BLOOD PRESSURE; HEART RATE; HUMANS; HYDROCORTISONE; MALE; MODELS, BIOLOGICAL; MODELS, PSYCHOLOGICAL; PANIC DISORDER; PERSONALITY INVENTORY; REFERENCE VALUES; TETRAGASTRIN;

EID: 34249881067     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0738-7     Document Type: Article

References (44)

1. Abelson JL, Liberzon I (1999) Dose response of adrenocorticotropin and cortisol to the CCK-B agonist pentagastrin. Neuropsychopharmacology 21:485-494
2. Abelson JL, Liberzon I, Young EA, Khan S (2005) Cognitive modulation of the endocrine stress response to a pharmacological challenge in normal and panic disorder subjects. Arch Gen Psychiatry 62:668-675
3. Ackenheil M, Stotz G, Dietz-Bauer R, Vossen A (1999) Mini International Neuropsychiatric Interview, German version 5.0.0
4. Akiyoshi J, Isogawa K, Tsutsumi T, Kasturagi S, Kohno K, Furuta M, Yamamoto Y, Yamada K, Fujii I (1997) Cholecystokinin tetrapeptide-induced calcium mobilization in T cells of patients with panic disorder, major depression, or schizophrenia. Biol Psychiatry 42:151-154
5. Aluoja A, Shlik J, Vasar V, Kingisepp PH, Jagomagi K, Vasar E, Bradwejn J (1997) Emotional and cognitive factors connected with response to cholecystokinin tetrapeptide in healthy volunteers. Psychiatry Res 66:59-67
6. Beinfeld MC, Meyer DK, Eskay RL, Jensen RT, Brownstein MJ (1981) The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay. Brain Res 212:51-57
7. Bradwejn J, Koszycki D (1994a) Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiatry 151:261-263
8. Bradwejn J, Koszycki D (1994b) The cholecystokinin hypothesis of anxiety and panic disorder. Ann NY Acad Sci 713:273-282
9. Bradwejn J, Koszycki D (2001) Cholecystokinin and panic disorder: past and future clinical research strategies. Scand J Clin Lab Invest 61(Suppl):19-27
10. Bradwejn J, Koszycki D, Meterissian G (1990) Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry 35:83-85
11. Bradwejn J, Koszycki D, Shriqui C (1991) Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry 48:603-610
12. Bradwejn J, Koszycki D, Payeur R, Bourin M, Borthwick H (1992) Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. Am J Psychiatry 149:962-964
13. Bradwejn J, Koszycki D, Couetoux du TA, van Megen H, den Boer J, Westenberg H (1994) The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 51:486-493
14. Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A (1995) Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biol Psychiatry 38:742-746
15. Bradwejn J, LeGrand JM, Koszycki D, Bates JH, Bourin M (1998) Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers. Am J Psychiatry 155:280-282
16. Brambilla F, Bellodi L, Perna G, Garberi A, Panerai A, Sacerdote P (1993) Lymphocyte cholecystokinin concentrations in panic disorder. Am J Psychiatry 150:1111-1113
17. de Montigny C (1989) Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings. Arch Gen Psychiatry 46:511-517
18. Dillon DJ, Gorman JM, Liebowitz MR, Fyer AJ, Klein DF (1987) Measurement of lactate-induced panic and anxiety. Psychiatry Res 20:97-105
19. Engel RR (2000) Minnesota Multiphasic Personality Inventory-2. In: Hathaway SR, Mc Kinley JC, Engel RPotTGv (eds) University of Minnesota, Minneapolis, MN
20. Flint AJ, Koszycki D, Vaccarino FJ, Cadieux A, Boulenger JP, Bradwejn J (1998) Effect of aging on cholecystokinin-induced panic. Am J Psychiatry 155:283-285
21. Kellner M, Yassouridis A, Jahn H, Wiedemann K (1997) Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder. Psychopharmacology (Berl.) 133:55-61
22. Kellner M, Yassouridis A, Hua Y, Wendrich M, Naber D, Wiedemann K (2002) Trait dissociation affects the behavioral response to cholecystokinin tetrapeptide in healthy man. Psychiatry Res 111:93-96
23. Kellner M, Muhtz C, Stark K, Yassouridis A, Arlt J, Wiedemann K (2005) Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results. Psychopharmacology (Berl) 179:310-315
24. Kennedy JL, Bradwejn J, Koszycki D, King N, Crowe R, Vincent J, Fourie O (1999) Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry 4:284-285
25. Khan S, Liberzon I, Abelson JL (2004) Effects of propranolol on symptom and endocrine responses to pentagastrin. Psychoneuroendocrinology 29:1163-1171
26. Koszycki D, Cox BJ, Bradwejn J (1993) Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers. Am J Psychiatry 150:1881-1883
27. Koszycki D, Zacharko RM, Bradwejn J (1996a) Influence of personality on behavioral response to cholecystokinin-tetrapeptide in patients with panic disorder. Psychiatry Res 62:131-138
28. Koszycki D, Zacharko RM, Le Melledo JM, Young SN, Bradwejn J (1996b) Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. Biol Psychiatry 40:648-655
29. Koszycki D, Zacharko RM, Le Melledo JM, Bradwejn J (1998) Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers. Depress Anxiety. 8:1-7
30. Le Melledo JM, Bradwejn J, Koszycki D, Bichet D (1995) Premenstrual dysphoric disorder and response to cholecystokinin-tetrapeptide. Arch Gen Psychiatry. 52:605-606
31. Le Melledo JM, Merani S, Koszycki D, Bellavance F, Palmour R, Gutkowska J, Steinberg S, Bichet DG, Bradwejn J (1999) Sensitivity to CCK-4 in women with and without premenstrual dysphoric disorder (PMDD) during their follicular and luteal phases. Neuropsychopharmacology 20:81-91
32. Le Melledo JM, Arthur H, Dalton J, Woo C, Lipton N, Bellavance F, Koszycki D, Boulenger JP, Bradwejn J (2001) The influence of Type A behavior pattern on the response to the panicogenic agent CCK-4. J Psychosom Res 51:513-520
33. Lines C, Challenor J, Traub M (1995) Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260. Br J Clin Pharmacol 39:235-242
34. Lydiard RB, Ballenger JC, Laraia MT, Fossey MD, Beinfeld MC (1992) CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. Am J Psychiatry 149:691-693
35. Moran TH, Robinson PH, Goldrich MS, McHugh PR (1986) Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res 362:175-179
36. Rehfeld JF, Neilson FC (1995) Molecular form and regional distribution of cholecystokinin in the central and peripheral nervous system. In: Bradwejn J, Vasar E (eds) Cholecystokinin and anxiety: from neuron to behaviour. Springer, Austin, pp 33-56
37. Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J (1997) Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 22:332-340
38. Strohle A, Holsboer F, Rupprecht R (2000) Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder. Neuropsychopharmacology 22:251-256
39. van Megen HJ, Westenberg HG, den Boer JA, Kahn RS (1996) Cholecystokinin in anxiety. Eur Neuropsychopharmacol 6:263-280
40. van Megen HJ, Westenberg HG, den Boer JA, Slaap B, Scheepmakers A (1997) Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology (Berl) 129:357-364
41. Wiedemann K, Jahn H, Yassouridis A, Kellner M (2001) Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings. Arch Gen Psychiatry 58:371-377
42. Zwanzger P, Baghai TC, Schuele C, Strohle A, Padberg F, Kathmann N, Schwarz M, Moller HJ, Rupprecht R (2001) Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology 25:699-703
43. Zwanzger P, Eser D, Aicher S, Schule C, Baghai TC, Padberg F, Ella R, Moller HJ, Rupprecht R (2003a) Effects of alprazolam on cholecystokinin- tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study. Neuropsychopharmacology 28:979-984
44. Zwanzger P, Eser D, Padberg F, Baghai TC, Schule C, Rotzer F, Ella R, Moller HJ, Rupprecht R (2003b) Effects of tiagabine on cholecystokinin- tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. Depress Anxiety 18:140-143